0.38p+0.03 (+6.67%)22 Jul 2025, 16:16
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

N4 Pharma PLC Fundamentals

Company NameN4 Pharma PLCLast Updated2025-07-22
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue832.280 mMarket Cap£3.33 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.1909Cash Equity Ratio0.9610
Quick Ratio5.0963Current Ratio6.24
Price To Book Value4.8193ROCE0

N4 Pharma PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

N4 Pharma PLC Company Financials

Assets202420232022
Tangible Assets000
Intangible Assets0£61,210.000
Investments000
Total Fixed Assets0£61,210.000
Stocks000
Debtors£7,841.00£3,644.00£27,000.00
Cash & Equivalents£625,972.00£1.03 m£1.92 m
Other Assets000
Total Assets£775,769.00£1.28 m£2.17 m
Liabilities202420232022
Creditors within 1 year£124,367.00£81,726.00£77,889.00
Creditors after 1 year000
Other Liabilities000
Total Liabilities£124,367.00£81,726.00£77,889.00
Net assets£651,402.00£1.19 m£2.09 m
Equity202420232022
Called up share capital£1.58 m£1.08 m£935,121.00
Share Premium£14.94 m£14.87 m£14.70 m
Profit / Loss-£1.22 m-£1.42 m-£1.19 m
Other Equity£647,647.00£1.13 m£2.09 m
Preference & Minorities£3,755.00£66,005.000
Total Capital Employed£651,402.00£1.19 m£2.09 m
Ratios202420232022
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.19091.19091.1909
Cash / Equity0.96100.96100.9610
EPS£-0.00-£0.01-£0.01
Cash Flow202420232022
Cash from operating activities-£971,500.00-£1.21 m-£828,263.00
Cashflow before financing-£401,140.00-£893,198.00£135,505.00
Increase in Cash-£401,140.00-£892,417.00£135,505.00
Income202420232022
Turnover£7,282.00£1,953.000
Cost of sales000
Gross Profit£7,282.00£1,953.000
Operating Profit00-£1.19 m
Pre-Tax profit-£1.22 m-£1.42 m-£1.19 m

N4 Pharma PLC Company Background

SectorHealthcare
ActivitiesN4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines.The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec and its liptide platform called ECP105.
Latest Interim Date24 Sep 2024
Latest Fiscal Year End Date6 Jun 2025

N4 Pharma PLC Directors

AppointedNamePosition
2017-05-03Professor Humayun Akhter MughalNon-Executive Director
2018-04-25Mr. Gavin John BurnellExecutive Director,Chief Executive Officer
2023-08-01Dr. John ChiplinNon-Executive Director,Chairman
2025-06-06Mr. Luke Sebastian Cairns Executive Director
2025-06-06Mr. Nigel TheobaldExecutive Director,Chief Executive Officer
2025-01-08Mr. David TempletonExecutive Director
2022-02-24Mr. Paul TitleyExecutive Director
2025-06-06Dr. Christopher Jonathan BrittenNon-Executive Director,Chairman
2025-06-06Dr. Michael G. PalfreymanNon-Executive Director
2025-04-04Dr. David Alastair Maclaughlin SmithNon-Executive Director
2025-07-08Mr. Edward WardleNon-Executive Director

N4 Pharma PLC Contact Details

Company NameN4 Pharma PLC
Address60 Gracechurch Street, 6th Floor, London, EC3V 0HR
Telephone+44 1332690061
Websitehttps://www.n4pharma.com

N4 Pharma PLC Advisors

SolicitorDWF LLP
Phone0113 261 6000
Fax0870 094 0939
AuditorSaffery Champness
Phone+44 2078414000
Fax+44 2078414100
Financial PR AdviserAlma PR
Phone+44 2080044217
Nominated AdviserStockdale Securities Ltd
Phone+44 2076016100
StockbrokerStockdale Securities Ltd
Phone+44 2076016100
SolicitorEdwin Coe LLP
Phone+44 2076914000
Fax+44 2076914111
AuditorJeffreys Henry LLP
Phone+44 2073092222
Fax+44 2073092309
BankNational Westminster Bank PLC
StockbrokerAllenby Capital Limited
Phone+44 2033285656
Fax+44 2033942970
Financial AdviserAllenby Capital Limited
Phone+44 2033285656
Fax+44 2033942970
RegistrarNeville Registrars Ltd
Phone+44 1215851131
Fax+44 1215851132